Overview

Macugen for Histoplasmosis

Status:
Terminated

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).

Phase:

N/A

Details

Lead Sponsor:

Barnes Retina Institute

Collaborator:

Pfizer